Compare Adaptive Biotechnologies Corp (ADPT) vs Starbucks Corp (SBUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Starbucks Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Starbucks Corp trades at $103.75 (market cap $118.08B). The key difference: Starbucks Corp is far larger — about 35.5× Adaptive Biotechnologies Corp's market cap, and Starbucks Corp pays a 2.39% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SBUX | |
|---|---|---|
Market Cap | $3.33B | $118.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $106.82 |
52-Week Low | $10.24 | $78.46 |
Enterprise Value | $3.19B | $140.78B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Starbucks (SBUX) trades at $103.61, down 0.62% with a bullish technical signal despite recent price weakness. The company shows mixed fundamentals with declining net income margins (3.89% in 2025) but stable revenue growth. Recent earnings beat expectations in Q1 2026 after two consecutive misses. Analyst consensus remains positive with a $107.67 price target, though technical indicators show neutral oscillators and key resistance at $104.
SBUX faces margin pressure but benefits from strong brand loyalty and store traffic initiatives. Investment opportunity lies in international expansion and operational improvements, while risks include competitive pressures and cost inflation. The stock offers moderate upside potential with balanced analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
